Search results for "Harm"

showing 10 items of 13866 documents

PACAP38 and PAC1 receptor blockade: a new target for headache?

2018

Abstract Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated. Migraine is a neurovascular disorder, recognized as the second most disabling disease. Nevertheless, the antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are the only prophylactic treatment developed specifically for migraine. These antibodies have displayed positive results in clinical trials, but are not effective for all patients; therefore, new pharmacol…

0301 basic medicineSide effectPAC1 receptorMigraine DisordersMigraine Disorders/drug therapylcsh:MedicinePituitary Adenylate Cyclase-Activating Polypeptide/antagonists & inhibitorsReview ArticleTriptansPharmacologyCalcitonin gene-related peptidePACAPNeuroprotectionmigraine; PAC1 receptor; PACAP; prophylactic treatment; animals; disease models animal; headache; humans; migraine disorders; pituitary adenylate cyclase-activating polypeptide; receptors pituitary adenylate cyclase-activating polypeptide type I; neurology (clinical); anesthesiology and pain medicine03 medical and health sciences0302 clinical medicineAnimalsHumansMedicineMigraine treatmentReceptorMigraineHeadache/drug therapybusiness.industrylcsh:RHeadacheGeneral Medicinemedicine.disease3. Good healthBlockadeDisease Models Animal030104 developmental biologyAnesthesiology and Pain MedicineMigrainePituitary Adenylate Cyclase-Activating PolypeptideNeurology (clinical)businessProphylactic treatment030217 neurology & neurosurgeryReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type IReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type I/antagonists & inhibitorsmedicine.drugJournal of Headache and Pain
researchProduct

Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization

2015

Imiquimod, a toll-like receptor 7 (TLR7) agonist, is an active pharmaceutical ingredient (API) established for the topical treatment of several dermal cancerous and precancerous skin lesions. Within this work, the immunostimulatory effect of imiquimod is further exploited in a transcutaneous immunization (TCI) approach based on a solid nanoemulsion (SN) formulation. SN contains a combination of imiquimod with the model peptide antigen SIINFEKL as a novel approach to omit needle and syringe and optimize dermal antigen administration. Excipients including sucrose fatty acid esters and the pharmaceutically acceptable oils MCT (middle chain triglycerides), avocado oil, jojoba wax and squalene a…

0301 basic medicineSkin NeoplasmsChemistry PharmaceuticalImmunologyAntineoplastic AgentsImiquimodImmunopotentiatorBiologyAdministration Cutaneous030226 pharmacology & pharmacyMice03 medical and health sciencesFreeze-dryingSqualenechemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineAdjuvants ImmunologicAntigenIn vivomedicineAnimalsHumansActive ingredientImiquimodChromatographyVaccinationPermeationNanostructuresMice Inbred C57BL030104 developmental biologychemistryLangerhans CellsImmunologyAminoquinolinesImmunizationOilsPrecancerous Conditionsmedicine.drugCellular Immunology
researchProduct

Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.

2017

Abstract Background The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic tumor setting. However, it does not accomplish memory formation or permanent defiance of tumors in a therapeutic set-up. As a distinct immunologic approach, CTLA-4 blockade augments systemic immune responses and has shown long-lasting effects in preclinical experiments as well as in clinical trials. Objective The study investigates the vaccination capacity of TCI in combination with the checkpoint inhibitor CTLA-4 in matter…

0301 basic medicineSkin NeoplasmsOvalbuminmedicine.medical_treatmentMelanoma Experimentalchemical and pharmacologic phenomenaDermatologyBiochemistryT-Lymphocytes RegulatoryEpitope03 medical and health sciencesMice0302 clinical medicineImmune systemAntineoplastic Agents ImmunologicalAdjuvants ImmunologicmedicineCytotoxic T cellAnimalsHumansCTLA-4 AntigenMolecular BiologyImiquimodMembrane Glycoproteinsbusiness.industryMelanomahemic and immune systemsDrug SynergismTLR7Immunotherapymedicine.diseaseFlow CytometryXenograft Model Antitumor AssaysPeptide FragmentsMice Inbred C57BLCTL*030104 developmental biologyToll-Like Receptor 7CTLA-4030220 oncology & carcinogenesisImmunologyAminoquinolinesImmunotherapybusinessImmunologic MemoryT-Lymphocytes CytotoxicJournal of dermatological science
researchProduct

From Genesis to Revelation: The Role of Inflammatory Mediators in Chronic Respiratory Diseases and their Control by Nucleic Acid-based Drugs.

2015

Asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis, are among the most common chronic diseases and their prevalence is increasing. Each of these diseases is characterized by the secretion of cytokines and pro-inflammatory molecules which are thought to play a critical role in their pathogenesis. Moreover, immune cells, particularly neutrophils, macrophages and dendritic cells as well structural cells such as epithelial and airway smooth muscle cells are also involved in the pathogenic cycle of these diseases. There is a pressing need for the development of new therapies for these pulmonary diseases, particularly as no existing treatment has bee…

0301 basic medicineSmall interfering RNARespiratory diseasessiRNA deliveryHMGB1 (high-mobility group box 1)medicine.medical_treatmentGenetic enhancementOligonucleotidesPharmaceutical Science02 engineering and technologyBiologySmall InterferingPathogenesis03 medical and health sciencesIdiopathic pulmonary fibrosisImmune systemRNA interferenceNucleic AcidsmedicineAnimalsHumansAntisenseHMGB1 ProteinRNA Small InterferingCatalyticLungNABDs deliveryDNADNA CatalyticGenetic TherapyOligonucleotides Antisense021001 nanoscience & nanotechnologymedicine.diseaseRespiration Disorders030104 developmental biologyCytokinemedicine.anatomical_structureImmunologyChronic DiseaseRNAInflammation Mediators0210 nano-technologyHMGB1 (high-mobility group box 1); Inflammation mediators; NABDs delivery; Respiratory diseases; siRNA delivery; Animals; Chronic Disease; DNA Catalytic; HMGB1 Protein; Humans; Inflammation Mediators; Nucleic Acids; Oligonucleotides Antisense; RNA Small Interfering; Respiration Disorders; Genetic TherapyCurrent drug delivery
researchProduct

P/CAF-mediated spermidine acetylation regulates histone acetyltransferase activity

2016

Histones and polyamines are important determinants of the chromatin structure. Histones form the core of nucleosome particles and their modification by acetylation of N-terminal tails is involved in chromatin structural changes and transcriptional regulation. Polyamines, including spermidine, are also targets of both cytoplasmic and nuclear acetylation, which in turn alters their affinity for DNA and nucleosomes. Previous studies report the interplay between polyamines metabolism and levels of histone acetylation, but the molecular basis of this effect is still unclear. In this work, we have analyzed the in vitro effect of spermidine on histone H3 acetylation catalyzed by P/CAF, a highly co…

0301 basic medicineSpermidine acetylationSpermidineSAP30BiologyHistones03 medical and health sciences0302 clinical medicineHistone H1Drug DiscoveryHistone H2AAnimalsHistone acetyltransferase activityp300-CBP Transcription FactorsHistone octamerHistone H3 acetylationHistone AcetyltransferasesPolytene ChromosomesPharmacologyAcetylationGeneral MedicineHistone acetyltransferaseEnzyme ActivationKineticsDrosophila melanogaster030104 developmental biologyBiochemistry030220 oncology & carcinogenesisbiology.proteinJournal of Enzyme Inhibition and Medicinal Chemistry
researchProduct

Synthesis and biofilm formation reduction of pyrazole-4-carboxamide derivatives in some Staphylococcus aureus strains

2016

The ability of several N-phenyl-1H-pyrazole-4-carboxamide derivatives and other pyrazoles opportunely modified at the positions 3, 4 and 5, to reduce the formation of the biofilm in some Staphylococcus aureus strains (ATCC 29213, ATCC 25923 and ATCC 6538) were investigated. All the tested compounds were able, although to a different extent, to reduce the biofilm formation of the three bacterial strains considered. Among these, the 1-(2,5-dichlorophenyl)-5-methyl-N-phenyl-1H-pyrazole-4-carboxamide 14 resulted as the best inhibitor of biofilm formation showing an IC50 ranging from 2.3 to 32 μM, against all the three strains of S. aureus. Compound 14 also shows a good protective effect in vivo…

0301 basic medicineStaphylococcus aureusmedicine.drug_class030106 microbiologyCarboxamideMothsN-phenyl-1H-pyrazole-4-carboxamidePyrazoleSettore BIO/19 - Microbiologia Generalemedicine.disease_cause01 natural sciencesMicrobiologyStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compoundDrug DiscoveryInhibition of biofilm formationmedicineAnimalsIC50PharmacologyWaxVirulencebiology010405 organic chemistryDrug Discovery3003 Pharmaceutical ScienceAnti-virulenceOrganic ChemistryBiofilmS. aureuGeneral MedicineStaphylococcal Infectionsbiology.organism_classificationSettore CHIM/08 - Chimica FarmaceuticaAnti-Bacterial Agents0104 chemical sciencesGalleria mellonellaHydrazinesSettore AGR/11 - Entomologia Generale E ApplicatachemistryStaphylococcus aureusBiofilmsLarvavisual_artWax moth larva modelvisual_art.visual_art_mediumPyrazolesLead compoundEuropean Journal of Medicinal Chemistry
researchProduct

Reverse screening on indicaxanthin from Opuntia ficus-indica as natural chemoactive and chemopreventive agent

2018

Indicaxanthin is a bioactive and bioavailable betalain pigment extracted from Opuntia ficus indica fruits. Indicaxanthin has pharmacokinetic proprieties, rarely found in other phytochemicals, and it has been demonstrated that it provides a broad-spectrum of pharmaceutical activity, exerting anti-proliferative, anti-inflammatory, and neuromodulator effects. The discovery of the Indicaxanthin physiological targets plays an important role in understanding the biochemical mechanism. In this study, combined reverse pharmacophore mapping, reverse docking, and text-based database search identified Inositol Trisphosphate 3-Kinase (ITP3K-A), Glutamate carboxypeptidase II (GCPII), Leukotriene-A4 hydr…

0301 basic medicineStatistics and ProbabilityMolecular dynamicPyridinesKainate receptorIndicaxanthinPhytochemical01 natural sciencesGeneral Biochemistry Genetics and Molecular BiologyDocking03 medical and health scienceschemistry.chemical_compoundNeoplasmsGlutamate carboxypeptidase IIData MiningHumansEnzyme InhibitorsMM-GBSAPharmacophore modelingBinding SitesGeneral Immunology and MicrobiologyReverse screening010405 organic chemistryAnti-cancerApplied MathematicsPhosphodiesteraseOpuntiaPhosphoserine phosphataseInositol trisphosphateGeneral MedicineAntineoplastic Agents Phytogenic0104 chemical sciencesBetaxanthinsNeoplasm ProteinsNeuromodulatorMolecular Docking SimulationAnti-inflammatory agent030104 developmental biologychemistryBiochemistryDocking (molecular)Modeling and SimulationPharmacophoreGeneral Agricultural and Biological SciencesIndicaxanthin
researchProduct

Exploring Strategies for Labeling Viruses with Gold Nanoclusters through Non-equilibrium Molecular Dynamics Simulations.

2017

Biocompatible gold nanoclusters can be utilized as contrast agents in virus imaging. The labeling of viruses can be achieved noncovalently but site-specifically by linking the cluster to the hydrophobic pocket of a virus via a lipid-like pocket factor. We have estimated the binding affinities of three different pocket factors of echovirus 1 (EV1) in molecular dynamics simulations combined with non-equilibrium free-energy calculations. We have also studied the effects on binding affinities with a pocket factor linked to the Au102pMBA44 nanocluster in different protonation states. Although the absolute binding affinities are over-estimated for all the systems, the trend is in agreement with r…

0301 basic medicineStereochemistryBiomedical EngineeringPalmitic AcidPharmaceutical ScienceMetal NanoparticlesBioengineeringProtonationMolecular Dynamics SimulationLigandsAntiviral AgentsNanoclusters03 medical and health sciencesMolecular dynamicschemistry.chemical_compoundCapsidCluster (physics)Moleculeta116OxazolesBinding affinitiesEnterovirusPharmacologyOxadiazolesBinding Sitesta114labeling virusesChemistryOrganic ChemistryBiocompatible materialCrystallography030104 developmental biologyThermodynamicsnon-equilibrium molecular dynamicsGoldgold nanoclustersHydrophobic and Hydrophilic InteractionsDerivative (chemistry)BiotechnologyBioconjugate chemistry
researchProduct

Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses

2015

Rhodamine 123 (R123) transport substrate sensitizes P-glycoprotein (P-gp) to inhibition by compound 2c (cis-cis) N,N-bis(cyclohexanolamine)aryl ester isomer in a concentration-dependent manner in human MDR1-gene transfected mouse T-lymphoma L5178 cells as shown previously. By contrast, epirubicin (EPI) concentration changes left unaltered 2c IC50 values of EPI efflux. To clarify this discrepancy, defined molecular docking (DMD) analyses of 12 N,N-bis(cyclohexanolamine)aryl esters, the highly flexible aryl ester analog 4, and several P-gp substrate/non-substrate inhibitors were performed on human P-gp drug- or nucleotide-binding domains (DBD or NBD). DMD measurements yielded lowest binding e…

0301 basic medicineStereochemistryCell Culture TechniquesCancer drug resistance; Molecular docking; NN-Bis(cyclohexanolamine)aryl ester; P-glycoproteinPlasma protein bindingP-glycoproteinTransfectionBiochemistryRhodamine 123Substrate Specificity03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineCell Line TumorAnimalsRhodamine 123ATP Binding Cassette Transporter Subfamily B Member 1Binding siteP-glycoproteinEpirubicinPharmacologyBinding SitesbiologyMolecular StructureArylEstersCancer drug resistanceNCyclohexanolsMolecular Docking SimulationProtein Transport030104 developmental biologychemistryDocking (molecular)030220 oncology & carcinogenesisMolecular dockingbiology.proteinN-Bis(cyclohexanolamine)aryl esterEffluxBinding domainProtein Binding
researchProduct

Metal Ions and Metal Complexes in Alzheimer's Disease.

2015

Background: Alzheimer’s disease (AD) is the most common form of dementia that seriously affects daily life. Even if AD pathogenesis is still subject of debate, it is generally accepted that cerebral cortex plaques formed by aggregated amyloid-β (Aβ) peptides can be considered a characteristic pathological hallmark. It is well known that metal ions play an important role in the aggregation process of Aβ. Methods: This review focuses on the anti-Aβ aggregation activity of chelating ligands as well as on the use of metal complexes as diagnostic probes and as potential drugs. Conclusion: While chelating agents, such as curcumin or flavonoid derivatives, are currently used to capture metal ions …

0301 basic medicineStereochemistryMetal ions in aqueous solutionchemistry.chemical_elementProtein aggregationImagingPathogenesis03 medical and health scienceschemistry.chemical_compoundProtein AggregatesAlzheimer DiseaseCoordination ComplexesMetals HeavyDrug DiscoveryAD drugmedicineDementiaAnimalsHumansChelationMetal ionPharmacologyAmyloid beta-PeptidesDrug Discovery3003 Pharmaceutical ScienceAnti-aβ aggregating agentmedicine.diseaseCombinatorial chemistryRuthenium030104 developmental biologychemistrySettore CHIM/03 - Chimica Generale E InorganicaCurcuminMetal complexeAlzheimer's diseaseAlzheimer’s diseaseCurrent pharmaceutical design
researchProduct